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Abstract
Background: Despite the current therapeutic options for the treatment of inflammatory bowel disease, surgery is
still frequently required in the emergency setting, although the number of cases performed seems to have
decreased in recent years.
The World Society of Emergency Surgery decided to debate in a consensus conference of experts, the main
pertinent issues around the management of inflammatory bowel disease in the emergent situation, with the need
to provide focused guidelines for acute care and emergency surgeons.
Method: A group of experienced surgeons and gastroenterologists were nominated to develop the topics
assigned and answer the questions addressed by the Steering Committee of the project. Each expert followed a
precise analysis and grading of the studies selected for review. Statements and recommendations were discussed
and voted at the Consensus Conference of the 6th World Society of Emergency Surgery held in Nijmegen (The
Netherlands) in June 2019.
Conclusions: Complicated inflammatory bowel disease requires a multidisciplinary approach because of the
complexity of this patient group and disease spectrum in the emergency setting, with the aim of obtaining safe
surgery with good functional outcomes and a decreasing stoma rate where appropriate.
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Background
Inflammatory bowel disease (IBD) encompasses a group
of chronic inflammatory disorders comprising most
commonly of ulcerative colitis (UC) and Crohn’s disease
(CD). The incidence of IBD appears to be rising in re-
cent decades. Ng et al. [1] reported that the highest
prevalence values were in Europe (UC 505 per 100 000
in Norway; CD 322 per 100 000 in Germany) and North
America (UC 286 per 100 000 in the USA; CD 319 per
100 000 in Canada). The prevalence of IBD exceeded
0.3% in North America, Oceania, and many countries in
Europe. Overall, the majority of studies on CD and UC
report stable or decreasing incidence of IBD in North
America and Europe. Since 1990, the incidence has been
rising in newly industrialized countries in Africa, Asia,
and South America, including Brazil [1]. The overall in-
cidence of UC in Europe, North America, and Oceania
is independent of gender. In CD, less consistent findings
have been reported, with some cohorts suggesting a fe-
male predominance in the incidence of CD and others
failing to find any gender difference. Differences in
gender-specific incidence exist, with a female predomin-
ance in CD in western populations and a male predom-
inance in eastern studies. No gender differences were
found in UC [2].
IBD typically manifests in the 2nd or 3rd decade of life.
Although their pathogenesis is still unclear, it is hypothe-
sized that chronic intestinal inflammation originates from
an overly aggressive mucosal immune response against lu-
minal bacteria in genetically susceptible subjects.
CD is characterized by transmural inflammation that
can occur in the entire gastrointestinal (GI) tract and
common localizations include the terminal ileum and
colon. Due to the transmural inflammation, complica-
tions may present such as abscesses and fistulas.
In contrast, UC demonstrates mucosal inflammation
and typically starts distally in the rectum, showing pro-
gression towards the more proximal colon. The disease
will mostly be limited to the colon and ileal involvement
is rare (backwash ileitis).
Diagnosis of IBD is generally made by assessment of
symptoms, biochemical markers, and colonoscopy com-
bined with radiology and histology. The different pheno-
types of IBD share common clinical features but may
have a heterogeneous presentation which includes ab-
dominal pain, vomiting, diarrhea, rectal bleeding, weight
loss, and anemia. Extra-intestinal manifestations such as
arthritis, skin disorders, and uveitis may also be present.
IBD is chronic and potentially disabling, frequently lead-
ing to hospitalizations, lower quality of life and inability to
work, with a substantial socio-economic impact [3].
IBD management aims to achieve induction of remis-
sion, followed by maintenance therapy to prevent recur-
rent disease flares.
IBD therapy is tailored and the choice of the treatment
regimen depends on several factors including the type,
distribution, and disease severity, as well as co-morbidity
and patient preferences. Generally, depending on the
level of severity, most patients with CD and to a lesser
extent those with UC will require immunosuppression
to control intestinal inflammation. Conventional im-
munosuppressive therapies include azathioprine, 6-
mercaptopurine, methotrexate, and 6-thioguanine. These
therapies may be necessary for many years, particularly
given the incurable nature of CD.
In case of insufficient response to immunosuppressive
treatment, or in case of intolerance, biologics are the
next line of therapy in a step-up approach. Different
mechanisms are currently available. Anti-TNF such as
infliximab, adalimumab, and golimumab are available
and usually the first biologic that is prescribed due to
the lower costs since the introduction of biosimilars and
good effectiveness/safety profile. Next line biologicals in-
clude vedolizumab (anti-integrin), preventing leukocyte
homing to the gut, and ustekinumab for CD blocking
the interleukin 12/23 pathway. Recently, tofacitinib was
approved for the treatment of UC, which is a JAK inhibi-
tor and belongs to the group of small molecules.
Despite the current therapeutic arsenal for the treat-
ment of IBD, surgery is still frequently required although
the number of cases performed seems to have decreased
in recent years. It is reported that the risk of first CD
surgery after 10 years of disease decreased from 44 to
21% in the last 2 decades in the UK [4], with the risk of
a second resection decreasing from 40 to 17%. This is
likely due to the introduction of anti-TNF therapy, as
well as improved multidisciplinary IBD management aid-
ing this development.
Similarly, colectomy rates in UC decreased in a pro-
spective Swiss cohort and the 5-, 10-, 15-, and 20-year
cumulative colectomy rates after diagnosis were 4.1%,
6.4%, 10.4%, and 14.4%, respectively [5]. Interestingly,
the vast majority of colectomies took place within the
first 10 years since diagnosis.
The improved outcomes for patients with CD are fur-
ther reflected in recent studies. For example, the
population-based cohort of South-Limburg (The
Netherlands) showed that hospitalization rate reduced
from 65.9% to 44.2% and the surgery rate from 42.9 to
17.4% at 5 years, respectively (both P<0.01) [6]. How-
ever, patients with CD still show progression towards a
complicated phenotype. This is characterized by the for-
mation of stenosis (stricturing phenotype) or abscess/fis-
tula (penetrating phenotype). In contrast, patients who
do not progress over time towards these phenotypes are
considered “inflammatory phenotype.” The latter study
showed that the rate of progression towards penetrating
or stricturing phenotype was around 21% in the 1990s
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and this rate did not change until 2011 when 2 different
time cohorts were analyzed. In contrast, the rate of im-
munosuppression increased from 30 to 70%, and bio-
logic use from 3 to 41%.
Thus, despite improved IBD management and decreas-
ing surgical rates, patients with complicated IBD con-
tinue to present with acute complications requiring
admission for emergency care. This is in part explained
by the progression towards a complicated phenotype
(structuring or penetrating phenotype). Secondly, pa-
tients have more therapeutic options and continue to be
treated with available biologics. When failure of biologic
therapy occurs, patients are usually more refractory and
prone to requiring hospitalization and surgery. Toxic
colitis with or without megacolon, massive hemorrhage,
free perforation, an acute abscess (either intra-
abdominal or perianal) with sepsis, and intestinal ob-
struction are examples of acute surgical emergencies [7].
CD can present with acute complications requiring emer-
gency surgery in approximately 6–16% of cases [8]. In acute
severe UC, intravenous corticosteroids remain the corner-
stone of medical therapy but about 30% of patients do not
respond to corticosteroids. After failing 3–5 days of cortico-
steroids, patients should be considered for second line
medical therapy in the form of cyclosporine or anti-TNF
therapy, as well as consideration and counselling for
colectomy.
Complicated IBD requires a multidisciplinary ap-
proach because of the complexity of this group of pa-
tients. The management of IBD is very well established
in the elective setting but is still unclear in the urgent/
emergency setting with a lot of grey areas and a highly
variable quality of management in the lack of established
consensus and guidelines that could lead to poor overall
and functional outcomes.
The World Society of Emergency Surgery (WSES) de-
cided to debate in a consensus conference of experts in
the fields, the main issues pertinent to the management of
IBD in the emergent situation, with the need to provide a
focused guide for acute care and emergency surgeons.
Materials and methods
During the 2018 WSES congress, the Scientific Board of
the WSES expressed the necessity to address the lack of
guidelines about the management of IBD in the emer-
gency setting, to improve outcomes, decreasing morbid-
ity, and mortality correlated to the emergency treatment
of these chronic and complex diseases.
Table 1 Summary of topics and PICO questions
Topic Question Combination of words
Initial
assessment and Diagnosis
Q.1: In patients with suspected complicated IBD, which are
the appropriate biochemical investigations that should be
performed?
“Crohn”, “Ulcerative colitis”, “abdominal pain”, “emergency”,




Q.2: In patients with a suspected complicated IBD, which
are the appropriate imaging studies that should be
performed in the emergency setting?
“Crohn”; “Ulcerative colitis”; “emergency”; “radiology”;
“computed tomography”; magnetic resonance”;




Q.3: Which is the role of interventional radiology in the
management of intra-abdominal abscesses related to
Crohn’s disease in the emergency setting?
“Crohn"; “abscess”; “stricture”; “drainage”; “antibiotics”;
“surgery”; “emergency”; “ulcerative colitis”
Preoperative
management
Q.4: In patients presenting with complications related to
IBD, what is the appropriate medical treatment and
nutritional support?
-The role of medical treatment and management of
specific IBD drugs
-The role of nutritional support
“Crohn”; "Ulcerative Colitis"; Nutritional support”;
“immunosuppression”; “steroids”; “biologics”; “medical











Q.5: What are the indications for emergency surgery in
patients presenting with complications related to IBD?





bleeding", "non operative management"
Surgical management Q.6: Which surgical approach is recommended for
complicated IBD in the emergency setting?
“Acute severe ulcerative colitis”; “intestinal bleeding”;
”hemorrage”;“Crohn”; “anastomosis”; “laparoscopy”; “open”;
“non operative management”; peritonitis”; “occlusion”;
“perforation”; “toxic megacolon”; minimally invasive
tecnique”; “emergency”;”damage control”;”open abdomen”
Surgical management Q.7: How to manage perianal sepsis in the emergency
setting?
“perianal”; “abscess”; “fistula”; “sepsis”;”antimicrobial”;
“medical treatment”; “surgery”;”emergency”, "Crohn"
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A group of experienced surgeons and gastroenterolo-
gists were nominated to develop the topics assigned and
answer the questions addressed by the Steering Commit-
tee (SC) of the project. The main topics debated are
summarised in the Table 1. The scientific coordinator of
the WSES IBD Guidelines supervised each step of litera-
ture searching, study selection, and the final presentation
of evidence.
Each expert followed the PRISMA methodology [9] in
the selection of papers to consider for review, and arti-
cles selected were included in the final analysis. Pediatric
patients were excluded. The study group developed a fo-
cused draft and a variable number of statements. Each
statement was evaluated according to the Grading of
Recommendations, Assessment, Development and
Evaluation (GRADE) [10].
The provisional statements and the supporting litera-
ture were reviewed and discussed with the WSES scien-
tific coordinator by email and modified if necessary. The
final data and contributions were presented at the 2019
WSES Congress at Nijmegen.
The WSES scientific coordinator of the project revised
the statements, wrote the recommendations based on Con-
sensus conference comments/suggestions, and wrote the
final draft. It was submitted to all authors for evaluation
and approval. All the comments and pertinent suggestions
were considered in the final manuscript. Complicated IBD
is defined as summarized in Table 2. Statements and rec-
ommendations are summarized in Table 3.
Clinicians and surgeons should be aware that these
guidelines should be considered as an adjunctive tool for
decision and management but they do not substitute for
the clinical judgment for individual patients.
Results
Q.1: In patients with suspected complicated IBD, which
are the appropriate biochemical investigations that
should be performed?
Statement 1.1
In clinical practice, the diagnosis of CD and UC is based
on a set of modalities including clinical, biochemical,
endoscopic, radiological, and histological diagnostics ra-
ther than a single reference standard (QoE low C).
Statement 1.2
In assessing an acute abdomen in patients with IBD, la-
boratory tests including full blood count, electrolytes,
liver enzymes, inflammatory biomarkers such as erythro-
cyte sedimentation rate (ESR) and C-reactive protein
(CRP), and serum albumin and pre-albumin (to assess
nutritional status and degree of inflammation) are
mandatory (QoE moderate B).
Statement 1.3
In case of a suspected IBD flare, infectious causes should
be ruled out, especially Clostridium difficile and Cyto-
megalovirus (QoE low C).
Recommendation
We recommend assessing Crohn’s disease or ulcerative
colitis disease activity in the urgent clinical situation by
performing the following laboratory tests: a full blood
count, including hemoglobin, leukocyte count, and
platelet count; serum C-reactive protein level, erythro-
cyte sedimentation rate; serum electrolytes; liver en-
zymes level; serum albumin; renal function; and fecal
calprotectin level, when it is possible. It is mandatory to
exclude any infectious diseases by performing blood-,
stool cultures, and toxin test for Clostridium difficile
(strong recommendation based on a moderate level of
evidence 1B).
Summary of evidence and discussion
In assessing a patient with acute abdominal pain in the
emergency room, the main laboratory tests requested
are full blood count (20.1%), electrolytes (19.1%), cardiac
enzymes (19.0%), and liver function tests (11.5%) [11].
In differentiating the cause underlying acute abdom-
inal pain, the diagnostic accuracy values of C-reactive
protein (CRP) and white blood cell count (WBC) can be
elevated [12].
IBD disease activity will usually impact laboratory tests
results with anemia, leukocytosis, thrombocytosis, ele-
vated liver enzymes, hypoalbuminemia, and increased in-
flammatory markers. In addition, therapies may cause
abnormalities in liver enzymes, leukocytes, and kidney
function. Consequently, for patients with IBD admitted
to the emergency room for evaluation, laboratory tests
should always include full blood count with differential,
comprehensive metabolic panel, liver enzymes, and
lipase.
CRP and fecal calprotectin (FC) are the most widely
used biomarkers for IBD evaluation. CRP is the inflam-
matory marker of choice as it is more sensitive than
erythrocyte sedimentation rate (ESR) for the evaluation
of acute abdominal pain in patients with IBD, and corre-
lates better with endoscopic disease activity in CD rather
than in UC [13, 14]. It should be noted that a normal





Acute severe colitis Acute severe colitis
Toxic megacolon Toxic megacolon
Uncontrolled bleeding Uncontrolled bleeding
Colonic perforation Free perforation
Abscess/fistula
Intestinal obstruction
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Table 3 Summary of statements and recommendations
Initial assessment and diagnosis
Q.1:
In patients with suspected complicated IBD, which are the appropriate biochemical investigations that should be performed?
Statement 1.1
In clinical practice, the diagnosis of Crohn’s Disease and Ulcerative Colitis is based on a set of modalities including clinical, biochemical, endoscopic,
radiological, and histological diagnostics rather than a single reference standard (QoE low C).
Statement 1.2
In assessing an acute abdomen in patients with IBD, laboratory tests including full blood count, electrolytes, liver enzymes, inflammatory biomarkers
such as erythrocyte sedimentation rate (ESR) and C Reactive Protein (CRP), serum albumin and pre-albumin (to assess nutritional status and degree of
inflammation) are mandatory (QoE moderate B).
Statement 1.3
In case of a suspected IBD flare, infectious causes should be ruled out, especially Clostridium difficile and Cytomegalovirus (QoE low C).
Recommendation 1
We recommend assessing Crohn’s disease or Ulcerative colitis disease activity in the urgent clinical situation by performing the following laboratory
tests: a full blood count, including haemoglobin, leukocytes count and platelet count; serum C-reactive protein level, erythrocyte sedimentation rate
level, serum electrolytes, liver enzymes level, serum albumin, renal function and faecal calprotectin level, when it is possible. It’s mandatory to exclude
any infectious diseases by performing blood-, stool cultures and toxin test for Clostridium difficile (Strong recommendation based on a moderate
level of evidence 1B).
Q.2:
In patients with a suspected complicated IBD, which are the appropriate imaging studies that should be performed in the emergency
setting?
Statement 2.1
Cross-sectional imaging (computed tomography, magnetic resonance imaging, ultrasonography) is recommended to detect strictures and extra-
luminal IBD complications including fistulae and abscesses (QoE C).
Statement 2.2
Computed tomography and Magnetic resonance imaging are the most sensitive and specific imaging tests for detecting abscesses and stenosis in
IBD (QoE B).
Statement 2.3
Contrast enhanced computed tomography is the key study in the emergency setting in assessing IBD extra-luminal complications such as abscesse
and fistulae, and a source of bleeding in the case of gastro-intestinal haemorrhage (QoE B).
Statement 2.4
The diagnostic accuracy of magnetic resonance enterography for assessing disease activity and complications related to IBD (including strictures) is
similar to CT scan with a decreased ionising radiation exposure (QoE C)
Statement 2.5
Point of Care ultrasonography can have a role in showing free fluid, abscesses or intestinal distention in the emergency department, particularly
when CT scan is not available (QoE C)
Statement 2.6
Sigmoidoscopy allows intra-luminal assessment of distal IBD disease activity, bleeding source identification and biopsies in an acute setting, when it
is available (QoE C).
Statement 2.7
In stable patients presenting with signs of gastrointestinal haemorrhage, computed tomography angiography should be considered to localise the
bleeding site before angio-embolisation or surgery, especially when endoscopic assessment is not available (QoE C)
Recommendations 2
We recommend investigating the acute abdomen in IBD patients with IV contrast-enhanced computed tomography scan in the emergency setting,
to exclude the presence of intestinal perforation, stenosis, bleeding and abscesses and to help guide decision making for immediate surgery or initial
conservative management (Strong recommendation based on low level evidence 1C).
We suggest performing a point of care ultrasonography (if skills are available) when computed tomography scan is not available, in order to assess
the presence of free intra-abdominal fluid, intestinal distension or abscess. The magnetic resonance enterography, (if available) is the preferred
technique to diagnose strictures, to differentiate fibrotic from inflammatory components and disease activity (Weak recommendation based on low
level evidence 2C).
In stable patients presenting with signs of gastrointestinal bleeding, we recommend performing a computed tomography angiography to localise
the bleeding site before angio-embolisation or surgery (Weak recommendation based on low level evidence 2C).
If computed tomography and ultrasonography are unavailable, we suggest referring stable patients to a hospital where 24/7 emergency imaging is
available (Weak recommendation based on very low level evidence 2D)
Preoperative management and non operative management
Q.3:
Which is the role of interventional radiology in the management of intra-abdominal abscesses related to Crohn’s disease in the
emergency setting?
Statement 3.1
Percutaneous drainage associated with antimicrobial treatment should be considered as first line treatment in the management of abscesses related
to Crohn’s disease, in stable patients (QoE C).
Statement 3.2
Small abscesses (< 3 cm) could be treated with intravenous antibiotics with a risk of recurrence, especially if associated with enteric fistula (QoE B)
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Table 3 Summary of statements and recommendations (Continued)
Statement 3.3
Percutaneous drainage of abscesses > 3 cm could avoid immediate surgery and should be used as a bridging procedure before elective surgery to
reduce the need for stoma creation and limit intestinal resection in malnourished and high risk patients (QoE C).
Statement 3.4
Surgery should be considered in the case of failure of percutaneous drainage and in patients with signs of septic shock (QoE C).
Statement 3.5
Surgery should be considered for patients with enteric fistulae and if clinical evidence of sepsis persists despite the initial treatment plan (QoE C).
Recommendations 3
We recommend performing radiological percutaneous drainage of intra-abdominal abscesses > 3 cm related to Crohn’s disease associated with early
empiric administration of antibiotics, to adapt these as soon as possible to microbiological cultures results. The antimicrobial therapy should be re-
evaluated according to patient’s clinical and biochemical features (Strong recommendation based on a low level evidence 1C).
We recommend administering an early empiric antimicrobial therapy in stable patients presenting with abscess < 3 cm, with close clinical and
biochemical monitoring (Strong recommendation based on a low level evidence 1C).
Q.4:
In patients presenting with complications related to IBD, what is the appropriate medical treatment and nutritional support?
a) The role of medical treatment and management of specific IBD drugs
Statement 4.1
The optimal management of IBD patients presenting with acute abdominal pain is multidisciplinary, involving a gastroenterologist and an acute care
surgeon (QoE C).
Statement 4.2
All IBD patients presenting with an acute abdomen should receive adequate volume of intravenous fluids, low-molecular-weight heparin for
thromboprophylaxis and electrolyte abnormalities and anaemia should be corrected (QoE C).
Statement 4.3
Antibiotics should not be routinely administered, but only if superinfection is considered and in the presence of an intra-abdominal abscess (QoE B).
Statement 4.4
In case of superinfection or abscesses, prompt antimicrobial therapy against Gr/−/ aerobic and facultative bacilli and Gr/+/streptococci and obligate
anaerobic bacilli is needed according to the epidemiology and resistance of the setting. Antimicrobial therapy duration depends on the patient’s
clinical feature and laboratory tests results such as serum CRP level. (QoE A)
Statement 4.5
The initial medical treatment for severe active UC is intravenous corticosteroids, in case of hemodynamic stability of the patient (QoE A).
Statement 4.6
The response to intravenous steroids should be best assessed by the third day (QoE C).
Statement 4.7
In non-responder hemodynamically stable patients, medical rescue therapy including infliximab in combination with a thiopurine, or ciclosporin
should be considered in a multidisciplinary approach (QoE B).
Statement 4.8
Infliximab should be considered if anti-inflammatory therapy for penetrating ileocecal Crohn’s disease is required, following adequate resolution of
intra-abdominal abscesses in a multidisciplinary approach (QoE C).
Statement 4.9
Preoperative treatments with immunomodulators associated with anti-TNF-α agents and steroids are risk factors for intra-abdominal sepsis in patients
requiring emergency resectional surgery (QoE B)
Statement 4.10
In complex perianal fistulizing disease infliximab or adalimumab can be used as first line therapy in combination with azathioprine following
adequate surgical drainage if indicated. A combination of ciprofloxacin and anti-TNF improves short term outcomes (QoE A).
b) The role of nutritional support
Statement 4.11
Preoperative nutritional support is mandatory in severely undernourished patients (QoE A)
Statement 4.12
Total Parenteral nutrition should be reserved for nutritionally deficient IBD patients unable to tolerate enteral nutrition and when the enteral route is
contraindicated, in critically ill patients presenting with signs of shock, intestinal ischemia, high output fistula, and/or severe intestinal haemorrhage
(QoE B)
Statement 4.13
Total parenteral nutrition is the mode of choice when emergency surgery is needed for complicated IBD (QoE A)
Recommendations 4
We recommend evaluating medical treatment in IBD patients presenting with acute abdominal pain and disease activity in a multidisciplinary
approach (Strong recommendation based on low level evidence 1C).
We recommend not routinely administrating antibiotics in IBD patients but only in the presence of superinfection, intra-abdominal abscesses, and
sepsis (Strong recommendation based on high level evidence1A)
We recommend administering antibiotics according to the epidemiology and resistance of the setting in a duration that depends on the patient’s
clinical and biolchemical findings. Antifungals should be reserved for high risk patients such as those with bowel perforation and recent steroid
treatment. (Strong recommendation based on high level evidence 1A)
We recommend administering as soon as possible venous thromboembolism prophylaxis with LMWH for the high risk of thrombotic events related
to complicated IBD and the emergency setting (Strong recommendation based on high level evidence 1A)
We recommend weaning off steroids (wean preoperatively, ideally 4 weeks) and stopping immunomodulators associated with anti-TNF-α agents
before surgery, as soon as possible to decrease the risk of postoperative complications, in accordance with a gastroenterologist (Strong
recommendation based on moderate level evidence 1B)
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Table 3 Summary of statements and recommendations (Continued)
We recommend administering nutritional support (parenteral or enteral, according to GI function and in conjunction with a dietician/nutrition team)
in IBD patients as soon as possible (Strong recommendation based on moderate level evidence 1B)
Non Operative vs Operative management
Q.5: What are the indications for emergency surgery in patients presenting with complications related to IBD?
Urgent surgical treatment is to be considered in the following clinical setting:
1) ACUTE SEVERE ULCERATIVE COLITIS
Statement 5.1.1
If a patient’s condition does not improve or deteriorates within 48 to 72 h from initiation of medical therapy, in acute severe ulcerative colitis second-
line therapy or surgery should be considered and discussed by the emergency surgeon and the gastroenterologist (QoE C)
Statement 5.1.2
In the event of surgical complications such as free perforation, life-threatening haemorrhage (unstable patients) or generalised peritonitis, immediate
surgery is recommended in acute severe ulcerative colitis (QoE B)
Statement 5.1.3
In case of no improvement with second line therapy, in discussion with the gastroenterologist, surgery is recommended in acute severe ulcerative
colitis (QoE C)
Statement 5.1.4
Subtotal colectomy with ileostomy is a safe and effective treatment for patients requiring emergency surgery for acute severe ulcerative colitis
presenting with massive colorectal haemorrhage (QoE B)
Recommendations 5.1
We suggest evaluating all hemodynamically stable patients presenting with acute severe ulcerative colitis in a multidisciplinary approach with the
gastroenterologist to decide on options for initial medical treatment (Weak recommendation based on low level evidence 2C)
We recommend performing emergency surgical exploration in hemodynamically unstable patients, according to damage control principles and in
patients presenting with colonic perforation. Subtotal colectomy with ileostomy is the surgical treatment of choice in patients acute severe ulcerative




In patients presenting with toxic megacolon complicated by perforation, massive bleeding (unstable patients), clinical deterioration and signs of
shock, surgery is mandatory (QoE A).
Statement 5.2.2
In patients presenting with toxic megacolon, showing no clinical improvement and biological signs of deterioration after 24–48 h of medical
treatment, surgery is mandatory (QoE B).
Recommendation 5.2
We recommend not delaying surgery in critically ill patients presenting with toxic megacolon (Strong recommendation based on low level evidence
1C)
3) UNCONTROLLED GASTROINTESTINAL BLEEDING
Statement 5.3.1
Pre-operative localisation of the bleeding site, with the aim of excluding an upper gastrointestinal or an anorectal bleeding may allow better
planning the surgical strategy (QoE C).
Statement 5.3.2
An upper and lower GI endoscopy should be the initial diagnostic procedure for nearly all stable patients presenting with acute gastro-intestinal
bleeding (QoE C).
Statement 5.3.3
Computed tomography angiography should be performed in patients with ongoing bleeding who are hemodynamically stable after resuscitation
(QoE C).
Statement 5.3.4
Surgical treatment is recommended in patients with life-threatening bleeding and persistent hemodynamic instability and in patients with acute
severe ulcerative colitis non-responders to medical treatment presenting with a massive colorectal haemorrhage (QoE B).
Statement 5.3.5
Significant recurrent gastrointestinal bleeding could be an indication for urgent surgery (QoE C).
Recommendations 5.3
We recommend performing immediate surgery in unstable patients presenting with hemorrhagic shock, and non responders to resuscitation. An
intra-operative ileoscopy, if available, could be useful in localising the bleeding source in patients with Crohn’s disease. In patients presenting with
acute severe ulcerative colitis and refractory haemorrhage, non responders to medical treatment, the surgical treatment of choice is a subtotal
colectomy with ileostomy, if skills are present (Strong recommendation based on low level evidence 1C).
We suggest evaluating hemodynamically stable IBD patients presenting with a gastrointestinal bleeding at first with a sigmoidoscopy and an
esophagogastroduodenoscopy (Weak recommendation based on low level evidence 2C)
4) FREE PERFORATION
Recommendation 5.4
We recommend performing surgical exploration in the presence of radiological signs of pneumoperitoneum and free fluid within the peritoneal
cavity in acutely unwell patients presenting with complicated Crohn’s disease or acute severe ulcerative colitis (Strong recommendation based on
low level evidence 1C)
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Table 3 Summary of statements and recommendations (Continued)
5) INTESTINAL OBSTRUCTION
Statement 5.5.1
Surgery is mandatory for symptomatic intestinal strictures that do not respond to medical therapy and are not amenable to endoscopic dilatation in
Crohn’s disease (QoE C).
Statement 5.5.2
Any colorectal stricture should be assessed with endoscopic biopsies to ensure the absence of malignancy (QoE C).
Recommendation 5.5
We recommend performing surgery in patients presenting with small bowel obstruction because of fibrotic or medically-resistant stenosis (Strong
recommendation based on low level evidence 1C)
Surgical management
Q.6:
Which surgical approach is recommended for complicated IBD in the emergency setting?
1) Emergency Surgery for ulcerative colitis
Statement 6.1.1
In the setting of free perforation and generalised peritonitis or toxic megacolon, in hemodynamically unstable patient, an open approach is
recommended (QoE C).
Statement 6.1.2
Both open and laparoscopic approaches are otherwise appropriate in the emergency setting, according to patient’s haemodynamic stability and
signs of sepsis in complicated ulcerative colitis (QoE C).
Statement 6.1.3
A laparoscopic approach (multi-port or in a single incision), if local expertise allows, may reduce length of stay and morbidity in hemodynamically
stable patients with complicated ulcerative colitis (QoE C)




If emergency surgery is indicated, a laparoscopic approach to adhesiolysis and bowel resection is recommended if appropriate expertise exists, with
care taken to avoid iatrogenic bowel injury in patients presenting intestinal obstruction in Crohn’s disease (QoE C)
b) Bleeding
Statement 6.2.2
If the patient presenting with gastrointestinal bleeding in Crohn’s disease is haemodynamically stable and endoscopic and/or interventional
radiology measures have been unsuccessful, then a surgical exploration in a laparoscopic (multi-port or in single incision) approach is recommended.
(QoE C)
Statement 6.2.3
If the patient presenting with gastrointestinal bleeding in Crohn’s disease is haemodynamically unstable and endoscopic and/or interventional
radiology procedures have been unsuccessful, then a surgical exploration in an open approach is recommended to reduce operating time (QoE C).
c) Free perforation and purulent/faecal peritonitis
Statement 6.2.4
A laparoscopic approach with resection, lavage and stoma is suggested in hemodynamically stable patients presenting with perforation and
peritonitis in Crohn’s disease, to avoid complications associated with anastomotic leak (QoE C)
Statement 6.2.5
If there is haemodynamic stability and only localised contamination, an anastomosis may be considered but other factors will also need to be
considered (QoE C)
Statement 6.2.6
If evidence of severe sepsis/septic shock, damage control surgery may be considered, with resection, stapled off bowel ends and temporary closure
(laparostomy) with return to theatre in 24–48 h for a second look, washout and consideration of stoma vs anastomosis (QoE C).
d) Crohn’s Colitis
Statement 6.2.7
Subtotal colectomy and ileostomy is the emergency operation of choice for severe acute and refractory colitis, with open and laparoscopic
approaches appropriate in the emergency setting, according to hemodynamic patient’s stability (QoE C).
Statement 6.2.8
A laparoscopic approach, if local expertise allows, may reduce length of hospital stay and risk of infectious complications (QoE C).
Statement 6.2.9
There is insufficient evidence to recommend SILS or robotic surgery in the emergency setting (QoE C).
3) Anastomotic considerations in emergency surgery for Crohn’s Disease
Statement 6.3.1
If a patient in the emergency setting has 2 or more risk factors for anastomotic complications, then a stoma should be formed following resection.
(QoE C)
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CRP does not rule out CD disease activity; therefore, the
results should be interpreted with caution given the low
sensitivity of this test.
The sensitivity of CRP ranges from 70 to 100% in the
differential diagnosis between CD versus irritable bowel
syndrome and ranges from 50 to 60% in UC [15]. Levels
of CRP are higher in active CD than in UC [16].
ESR determination monitors satisfactorily the acute-
phase response of IBD after the first 24 h. In contrast,
during the first 24 h, the CRP is a better indicator of the
acute phase. The ESR, compared with CRP, reaches the
highest point less quickly, and it decreases more slowly
and has a lesser degree of change [17].
Previous studies assessing the best monitoring of med-
ical treatment measured prospectively some laboratory
parameters such as full blood count, CRP, ESR, alfa1
antitrypsin, and orosomucoid in CD patients every 6
weeks after recent weaning of steroids [17] and showed
that the best predictor of short-term relapse is the com-
bination of CRP and ESR. Patients with CRP > 20 mg/L
and ESR > 15 mm had an eight-fold increased risk of re-
lapse with a negative predictive value of 97%, suggesting
that normal CRP and ESR could almost exclude relapse
in the next 6 weeks.
Anti-inflammatory or immunosuppressive drugs do
not affect CRP production. Therefore, changes of CRP
Table 3 Summary of statements and recommendations (Continued)
Statement 6.3.2
If a decision to anastomose has been made, there is no evidence to suggest that one type of anastomosis (stapled vs hand sewn) is superior to the
other in terms of complication rates or recurrence, and the decision can be left to surgeon preference (QoE C).
Recommendations 6
We recommend performing a surgical exploration by laparotomy in a hemodynamically unstable patient presenting with complications related to
IBD such as perforation and severe peritonitis, massive intestinal bleeding, obstruction, toxic megacolon, severe colitis non responder to medical
treatment, taking in to consideration damage control surgery principles with or without an open abdomen (Strong recommendation based on low
level evidence 1C).
We recommend performing a laparoscopic approach in hemodynamically stable patients presenting with complications related to IBD, when skills
are available, in order to decrease morbidity and length of hospital stay (Strong recommendation based on low level evidence 1C).
We recommend performing a subtotal colectomy with ileostomy in patients presenting with acute severe refractory colitis, and massive colorectal
bleeding non responders to medical treatment, in a laparoscopic or open approach according to patient’s hemodynamic stability and surgeon’s skill
(Strong recommendation based on low level evidence 1C).
We suggest considering an (stapled or hand sewn) anastomosis in hemodynamically stable patients with Crohn’s disease who have good pre-
existing nutritional status and who are taking no steroids or other immunosuppression and presenting with no bowel vascular compromise and only
localised peritonitis. A defunctioning stoma should also be considered in the emergency setting. (Weak recommendation based on low level
evidence 2C)
Q.7:
How to manage perianal sepsis in the emergency setting?
Statement 7.1
An acute abscess should be adequately drained under general anaesthetic, with no routine requirement for wound packing. (QoE C)
Statement 7.2
No active attempt should be made to find an associated anal fistula at the initial abscess presentation. (QoE C)
Statement 7.3
If an obvious fistula exists (without probing), the fistula should not be laid open and a loose draining seton should be inserted (QoE C)
Statement 7.4
There is no role for any additional surgical fistula treatment modality in the emergency treatment of Crohn’s perianal sepsis. (QoE C)
Statement 7.5
An assessment of the rectum should be made at the time of abscess drainage, to assess for signs of proctitis. (QoE C)
Recommendation 7
We recommend performing adequate surgical drainage of perianal abscess in Crohn’s disease without searching for an associated fistula (Strong
recommendation based on low level evidence 1C)
Table 4 Classification of ulcerative colitis per Truelove and Witts criteria at admission
Variables Mild Moderate Severe
Stool frequency/day ≤4 per day 4–6 per day ≥6 per day
Blood in stool None or small - Present
Temperature Apyrexial Intermediate >37.8
Heart rate bpm <90min/min Intermediate >90/min
Anemia (Hb=g/dL) >11 10.5–11 <10.5
Erythrocite sedimentation rate (mm/hour) <20 20–30 >30mm/h
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concentrations during treatment occur only as a result
of the effect of the drug on the inflammation or
disorder.
In addition, in assessing acute severe UC, defining the
population by Truelove Witts criteria (summarized in
Table 4) is essential [18]. The Truelove-Witts criteria
combine frequency of bloody stools (⩾6 per day) with at
least one marker of systemic toxicity such as pulse rate
>90 bpm, temperature >37.8°C, hemoglobin <10.5 g/dl,
and/or an ESR >30 mm/h. In patients with UC, the risk
of progression to the second-line therapy is directly
dependent on the number of variables present on admis-
sion, with a 50% risk for colectomy when three or more
additional criteria are present [19]. After 3 days of inten-
sive treatment (hydrocortisone and/or cyclosporine/anti-
TNF) patients with frequent stools (> 8/day), or 3–8
stools/day and CRP > 45 mg/L, should be identified and
reviewed jointly by a gastroenterologist and surgeon as
most of them will need to undergo colectomy [19].
Thrombocytosis correlates well with IBD disease se-
verity, and, interestingly, it may persist even after bowel
resection in some patients with IBD. The mean platelet
volume has been proposed as a potential marker of clin-
ical disease activity, being inversely proportional to the
levels of CRP and ESR. The cause of the reduction in
platelet volume in clinically active UC is unknown, but it
may be a direct result of the thrombopoiesis disorder
often observed in the early phases of systemic inflamma-
tory progression [20]. The platelets also relate to the in-
creased incidence of thromboembolic phenomena in CD
and UC. Some studies report that spontaneous platelet
aggregation is observed in more than 30% of patients
with IBD [21].
The number of white blood cells (WBC) increases dur-
ing the acute phase response, and it is influenced by im-
munosuppressive drugs utilized in IBD, such as
glucocorticoids (increased WBC) or azathioprine and 6-
mercaptopurine (decreased WBC).
Serum albumin is a negative acute phase marker and
decreased levels may be found during inflammation [16].
Fecal calprotectin (FC) is a granulocyte-derived pro-
tein measured in the stool and is a non-invasive, cheap,
and extensively studied biomarker used in IBD which
correlates with clinical and endoscopic disease activity
[14]. A cutoff of 30 μg/g had 100% sensitivity in discrim-
inating active CD from irritable bowel syndrome in the
study of Tibble and colleagues [22]
The correlation with disease activity is less robust for
disease localised to the terminal ileum (versus distal co-
lonic disease), with likelihood of false negative results in
case of proximal disease. Most hospitals will not have an
immediate assay ready for same-day results, so this can
limit the application of this marker in an emergency
setting.
In a patient with diarrhoea, stool cultures should be
obtained. In particular, fever and sudden onset of symp-
toms may direct the differential diagnosis towards an in-
fection. In the latter setting, bacterial stool culture or
PCR, and especially C. difficile toxin, must be consid-
ered. IBD patients are at increased risk for C difficile and
subsequent hospitalization and colectomy [23]. In
addition, corticosteroids seem to be an independent risk
factor for presenting with infectious colitis [24]. Depend-
ing on the clinical setting, PCR for viral and parasitic
agents may be considered. For example, IBD patients re-
ceiving immunosuppression are more prone to CMV
colitis, which can be measured in serum and biopsies
[25]. Blood cultures are mandatory.
Clinical evaluation and laboratory tests are useful to
stratify IBD patients in to low and high risk of compli-
cated disease.
Khoury et al. [26] developed a diagnostic clinical score
to predict the presence of an intra-abdominal abscess in
CD patients presenting with acute abdominal pain in the
ED. This score included 5 parameters that were signifi-
cantly associated with abscess formation, such as ileo-
colonic location of the disease, perianal CD, neutrophil-
to-lymphocyte ratio, and CRP level, whereas the current
use of corticosteroids was negatively associated with ab-
scess formation.
Q.2: In patients with a suspected complicated IBD, which
are the appropriate imaging studies that should be
performed in the emergency setting?
Statement 2.1
Cross-sectional imaging (computed tomography, mag-
netic resonance imaging, ultrasonography) is recom-
mended to detect strictures and extra-luminal IBD
complications including fistulae and abscesses (QoE C).
Statement 2.2
Computed tomography and magnetic resonance imaging
are the most sensitive and specific imaging tests for de-
tecting abscesses and stenosis in IBD (QoE B).
Table 5 Montreal classification for Crohn’s disease phenotype











p: modifier for perianal disease
De Simone et al. World Journal of Emergency Surgery           (2021) 16:23 Page 10 of 27
Statement 2.3
Contrast-enhanced computed tomography is the key
study in the emergency setting in assessing IBD extra-
luminal complications such as abscesse and fistulae, and
a source of bleeding in the case of gastro-intestinal
haemorrhage (QoE B).
Statement 2.4
The diagnostic accuracy of magnetic resonance entero-
graphy for assessing disease activity and complications
related to IBD (including strictures) is similar to CT
scan with a decreased ionising radiation exposure (QoE
C)
Statement 2.5
Point of care ultrasonography can have a role in showing
free fluid, abscesses, or intestinal distention in the emer-
gency department, particularly when CT scan is not
available (QoE C)
Statement 2.6
Sigmoidoscopy allows intra-luminal assessment of distal
IBD disease activity, bleeding source identification, and
biopsies in an acute setting, when it is available (QoE C).
Statement 2.7
In stable patients presenting with signs of gastrointes-
tinal hemorrhage, computed tomography angiography
should be considered to localize the bleeding site before
angio-embolization or surgery, especially when endo-
scopic assessment is not available (QoE C)
Recommendations
We recommend investigating the acute abdomen in IBD
patients with IV contrast-enhanced computed tomog-
raphy scan in the emergency setting, to exclude the pres-
ence of intestinal perforation, stenosis, bleeding, and
abscesses and to help guide decision making for immedi-
ate surgery or initial conservative management (strong
recommendation based on low-level evidence 1C).
We suggest performing a point of care ultrasonog-
raphy (if skills are available) when computed tomog-
raphy scan is not available, in order to assess the
presence of free intra-abdominal fluid, intestinal disten-
sion, or abscess. The magnetic resonance enterography
(if available) is the preferred technique to diagnose stric-
tures, to differentiate fibrotic from inflammatory compo-
nents and disease activity (weak recommendation based
on low-level evidence 2C).
In stable patients presenting with signs of gastrointes-
tinal bleeding, we recommend performing a computed
tomography angiography to localize the bleeding site be-
fore angio-embolization or surgery (weak recommenda-
tion based on low-level evidence 2C).
If computed tomography and ultrasonography are un-
available, we suggest referring stable patients to a hos-
pital where 24/7 emergency imaging is available (weak
recommendation based on very low-level evidence 2D)
Summary of evidence and discussion
An accurate acute abdominal assessment in patients in
the emergency room with IBD is crucial to aid an early
diagnosis and optimal treatment plan. Symptoms may
result from the underlying IBD, or disease complica-
tions, but can also reflect a complication of therapy, an
infection, or a separate medical problem. Imaging stud-
ies are mandatory to assess disease phenotype and com-
plications, in order to facilitate informed decision
making.
Usually, a cross-sectional study involving ultrasound
(US), computed tomography (CT) or magnetic reson-
ance imaging (MRI), allows for a full thickness evalu-
ation of the bowel wall and associated abnormalities.
The potential benefits of cross-sectional imaging in pa-
tients with IB include better inflammation grading, such
as identification of mild degree of activity, which may be
relevant whenever assessing response to treatment and,
of utmost importance, an accurate preoperative detec-
tion and grading of fibrosis in stricturing CD, facilitating
surgical versus medical therapeutic decisions.
The Truelove-Witts classification for UC and the
Montreal classification (summarized in Tables 4 and 5)
to assess CD phenotype are frequently used to stratify
IBD patients at admission, and they require laboratory
test and abdominal imaging results.
It is fundamental in an emergency to check the IBD
disease activity and extent. In CD, the disease behavior
can progress towards a penetrating phenotype over time,
and in UC, can involve all of the colon.
In the emergency setting, CT should be the first radio-
logical investigation to assess the acute abdomen in this
group of patients, especially in the case of a suspected
intra-abdominal abscess, perforation, or intestinal ob-
struction due to stricture(s). Using surgery as a reference
standard, CT showed a sensitivity of 85% and a specifi-
city of 88% for the detection of intra-abdominal ab-
scesses [27].
Moreover, it is useful to stratify patients for immediate
surgery or a medical treatment plan in assessing the type
of bowel strictures; in fact, inflammatory strictures could
benefit from a medical anti-inflammatory treatment, and
fibrotic strictures could require endoscopic balloon dila-
tion or surgery.
US showed specificity and sensitivity of 86% and 94%
in detecting small bowel inflammation in comparison
with MRI sensitivity and specificity that is 74% and 91%,
respectively, in expert hands [28, 29].
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A systematic review [30] showed that conventional
trans-abdominal US sensitivity for stricture diagnosis
ranged from 80 to 100% with specificity rates of 63–
75%. The application of small intestinal contrast US
demonstrated increased sensitivity rates of 88–98% with
specificity rates ranging from 88 to 100%. CT enterogra-
phy (CTE) sensitivity and specificity were reported to be
both 100%. CT enteroclysis, in which the luminal con-
trast is delivered direct to the small bowel, had a sensi-
tivity of 92% and specificity of 39% reported in one
study only. With regard to magnetic resonance imaging
enterography (MRE), the sensitivity for stricture detec-
tion ranged from 75 to 100% with specificity between
91% and 96% [30].
In a prospective blinded study, Point of Care US
(POCUS) demonstrated that it is an accurate technique in
defining disease activity and extent in IBD compared to
ileocolonoscopy with the advantage of being non-invasive.
It showed a 91% sensitivity and 83% specificity for detect-
ing endoscopically active IBD, correlating with a positive
predictive value (PPV) of 89%, a negative predictive value
(NPV) of 86%, and a kappa coefficient of 0.74 (88%).
POCUS-defined disease extent has a 87% sensitivity and
81% specificity, correlating with a PPV of 85% and NPV of
83% and a kappa coefficient of 0.70 (85%) [31].
Strictures can be assessed reliably by both CT and
MRI. Sensitivity was 85% vs 92% and specificity was
100% vs 90%, respectively [32]. In addition, CTE is a mo-
dality that can be applied and it will provide a more de-
tailed assessment of the bowel wall. However, the need
for large volume oral contrast prohibits its use in the
emergency setting.
In a prospective cohort study (31 participants), Mao
et al. demonstrated that intra-cavitary contrast-enhanced
US (IC-CEUS) could be a valid, radiation-free, safe, op-
tional method to detect a fistulous tract associated with
abscesses in CD patients with a sensitivity and specificity
of 86.7% (95% confidence interval [CI], 68.4–95.6%) and
100% [95% CI, 5.5–100.0%], respectively. Moreover, au-
thors reported that combining IC-CEUS and CTE/mag-
netic resonance imaging enterography (MRE), the
fistula/sinus tract was clearly demonstrated in 29 pa-
tients [93.5%, 29/31]. The mean duration of the IC-
CEUS procedure was 8.6 min [range 5.0–12.0] [33].
However, this technique is not widely used.
In clinical practice, MRE is frequently used in the out-
patient setting. The lack of radiation and the excellent
quality of images are advantages of this technique. This
is particularly applied for evaluation of the small bowel
and perineum. However, the use in an emergency setting
is limited due to the oral contrast, increased study time,
costs, and lack of availability.
In stable patients presenting with signs of GI
hemorrhage, CT angiography should be considered to
localize the bleeding site before angio-embolization or
surgery, when an endoscopic evaluation is not possible
and the patient is unable to tolerate the bowel prepar-
ation. A systematic review showed high sensitivity
(85.2%) and high specificity (92.1%) of CT angiography
for diagnosing acute gastrointestinal bleeding [34].
Endoscopy may be of added value as a diagnostic pro-
cedure for selected patients with IBD presenting with
lower GI-bleeding in an emergency setting. A full colon-
oscopy is usually not possible given the need for oral
bowel preparation prior to the colonoscopy, as well as
the inability for oral intake of large volumes. However, a
flexible sigmoidoscopy is possible with preparation with
an enema. This procedure can aid in establishing the
level and location of disease activity in UC and distal co-
lonic CD and to detect preoperatively a source of bleed-
ing. In addition, it can be used to rule out other
conditions such as colonic ischemia, infections, and can-
cer. Finally, biopsies may be obtained for histologic as-
sessment. A sigmoidoscopy will come with insufflation
so should therefore not be applied in patients with ob-
struction or toxic megacolon given the increased risk of
intestinal perforation.
Q.3: Which is the role of interventional radiology in the
management of intra-abdominal abscesses related to
Crohn’s disease in the emergency setting?
Statement 3.1
Percutaneous drainage associated with antimicrobial
treatment should be considered as a first-line treatment
in the management of abscesses related to Crohn’s dis-
ease, in stable patients (QoE C).
Statement 3.2
Small abscesses (<3 cm) could be treated with intraven-
ous antibiotics with a risk of recurrence, especially if as-
sociated with enteric fistula (QoE B)
Statement 3.3
Percutaneous drainage of abscesses > 3 cm could avoid
immediate surgery and should be used as a bridging pro-
cedure before elective surgery to reduce the need for
stoma creation and limit intestinal resection in malnour-
ished and high-risk patients (QoE C).
Statement 3.4
Surgery should be considered in the case of failure of
percutaneous drainage and in patients with signs of sep-
tic shock (QoE C).
Statement 3.5
Surgery should be considered for patients with enteric
fistulae and if clinical evidence of sepsis persists despite
the initial treatment plan (QoE C).
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Recommendations
We recommend performing radiological percutaneous
drainage of intra-abdominal abscesses >3cm related to
Crohn’s disease associated with early empiric adminis-
tration of antibiotics, to adapt these as soon as possible
to microbiological culture results. Antimicrobial therapy
should be re-evaluated according to patient’s clinical and
biochemical features (strong recommendation based on
a low-level evidence 1C).
We recommend administering an early empiric anti-
microbial therapy in stable patients presenting with ab-
scess <3cm, with close clinical and biochemical
monitoring (strong recommendation based on a low-
level evidence 1C).
Summary of evidence and discussion
Abscess, fistula, bleeding, and stenosis are common
complications of CD. Various interventional radiological
techniques can be considered as a first-line option for
non-operative treatment, with good outcomes. In case of
intestinal obstruction for stenosis, bowel dilatation can
be performed both with radiological and with endo-
scopic guidance, in stable patients. Embolization of GI-
hemorrhage is technically feasible, but it should be lim-
ited to strictly selected cases [35].
Intra-abdominal abscesses in patients with CD typic-
ally result from a perforation or penetrating ulcers, and
they are an expression of luminal disease activity associ-
ated with transmural translocation of bacteria from the
diseased bowel to contiguous tissue. Abscesses may be
intraperitoneal, retroperitoneal, or intra-mesenteric,
most frequently located in the right lower quadrant adja-
cent to the terminal ileum. In the literature, occurrence
rates for intra-abdominal abscesses vary from 10 to 30%
[36–39]. Active IBD warrants medical treatment, but the
presence of an abscess contraindicates immunosuppres-
sive medication.
There are several treatment options for intra-
abdominal abscesses in CD. Previously, the majority of
abscesses were treated with operative drainage, but with
the improvement of interventional radiological tech-
niques, the use of percutaneous drainage (PD) is increas-
ing, associated with administration of antibiotics.
Success rates for PD in the literature vary from 74 to
100% [36–39]. There are no RCTs comparing percutan-
eous and surgical drainage, but two meta-analyses tried
to clarify the role of percutaneous drainage, compared to
surgical management.
He et al. in 2015 [39] aimed to compare clinical out-
comes between PD alone and preoperative percutaneous
drainage and initial surgery for patients with CD-related
spontaneous intra-abdominal abscess, performed a
meta-analysis of 9 (non-randomized and retrospective)
studies including 513 patients and found a reduction in
stoma creation rate and complication rate for patients
undergoing pre-operative PD. The reason for these im-
proved outcomes could be related to an improvement in
patients’ general and nutritional condition prior to de-
finitive surgical intervention and to the control of the in-
fectious source. Moreover, they reported that the risk for
recurrent abscess was higher in patients who underwent
PD alone than those who underwent initial surgery,
highlighting that delayed abdominal surgery is almost in-
evitable in the majority of the patients presenting with
intra-abdominal abscess.
Another meta-analysis, including six studies with a
total of 333 patients was performed by Clancy et al. in
2016 [40]. They compared the use of PD alone and sur-
gery in the management of patients presenting with a
CD-related intra-abdominal abscess and reported an in-
creased incidence of abscess recurrence for patients
undergoing only PD, but interestingly, they also found
that PD can successfully avoid surgery in 29.3% of pa-
tients. In addition, they found no significant difference
in the overall complication rate, permanent stoma re-
quirement, or length of stay between patients undergo-
ing percutaneous drainage or immediate surgery.
PD (guided by US or CT) appears to be a relatively
safe procedure as part of a bridge to surgery technique,
but not all abscesses are “drainable” or “accessible.” Ef-
fectiveness depends on abscess characteristics, such as
location, number, size, presence of fistulae, or close
proximity to vital structures.
Independent risk factors for PD failure are bowel wall
thickness, disease length, bowel dilation, and abscess size
of greater than 6 cm. Furthermore, multiple percutan-
eous drainage procedures have been required in 8–20%
of patients [41] and it could increase the risk of compli-
cations such as damage to vital structures in close prox-
imity to the abscess or severe hemorrhage.
Complications of PD, for both spontaneous and post-
surgical abscesses (not specific to CD), occur in approxi-
mately 10% of procedures. Major complications such as
sepsis, small bowel fistulae, colon perforation, and death
(due to sepsis or hemorrhage) have been described in 5–
11% of cases. Minor complications (such as bacteremia
or infection at the site of the catheter insertion) occur in
approximately 3% [41].
Feagins et al. [42] suggested that non-drainable ab-
scesses smaller than 3 cm and without evidence of fistula
and no steroid therapy are likely to respond to antibiotic
therapy alone although with high recurrence rates. In
this setting, antibiotics should cover Gram-negative bac-
teria and anaerobes and it is important to closely ob-
serve the clinical condition of the patient in case of any
deterioration.
Antibiotic therapy, including a combination of fluoro-
quinolones or third-generation cephalosporin and
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metronidazole in patients with CD, should be adapted to
the sensitivity of the bacteria (and sometimes fungi) to
antibiotics, if PD is performed [43–45]..
The appropriate duration of antibiotic therapy is un-
clear. Clinical improvement should be seen within 3–5
days after starting antibiotics and percutaneous drainage,
with a decrease in drainage production. If a patient’s
condition does not improve, re-evaluation and repeat
imaging are indicated to determine whether the abscess
has been adequately drained. If not, repositioning of the
drain or surgical intervention is required [43–45].
If sepsis is controlled after adequate PD, CD medica-
tion should be started to prevent recurrence. Patients
with a concomitant stenosis, an entero-cutaneous fistula
or refractory active disease are likely to require surgery,
but preoperative PD, if it is feasible, associated with de-
layed surgery, can decrease the extent of intestinal resec-
tion, postoperative septic complications, and potentially
reduce stoma rates.
Q.4: In patients presenting with complications related to
IBD, what is the appropriate medical treatment and
nutritional support?
a) The role of medical treatment and management of
specific IBD drugs
Statement 4.1 The optimal management of IBD pa-
tients presenting with acute abdominal pain is multidis-
ciplinary, involving a gastroenterologist and an acute
care surgeon (QoE C).
Statement 4.2 All IBD patients presenting with an acute
abdomen should receive adequate volume of intravenous
fluids, low molecular weight heparin for thrombopro-
phylaxis and electrolyte abnormalities and anaemia
should be corrected (QoE C).
Statement 4.3 Antibiotics should not be routinely ad-
ministered, but only if superinfection is considered and
in the presence of an intra-abdominal abscess (QoE B).
Statement 4.4 In case of superinfection or abscesses,
prompt antimicrobial therapy against Gr/-/aerobic and
facultative bacilli and Gr/+/streptococci and obligate an-
aerobic bacilli is needed according to the epidemiology
and resistance of the setting. Antimicrobial therapy dur-
ation depends on the patient's clinical feature and labora-
tory test results such as serum CRP level (QoE A).
Statement 4.5 The initial medical treatment for severe
active UC is intravenous corticosteroids, in case of
hemodynamic stability of the patient (QoE A).
Statement 4.6 The response to intravenous steroids
should be best assessed by the third day (QoE C).
Statement 4.7 In non-responder hemodynamically
stable patients, medical rescue therapy including inflixi-
mab in combination with a thiopurine or ciclosporin
should be considered in a multidisciplinary approach
(QoE B).
Statement 4.8 Infliximab should be considered if anti-
inflammatory therapy for penetrating ileocecal Crohn’s
disease is required, following adequate resolution of
intra-abdominal abscesses in a multidisciplinary ap-
proach (QoE C).
Statement 4.9 Preoperative treatments with immuno-
modulators associated with anti-TNF-α agents and ste-
roids are risk factors for intra-abdominal sepsis in
patients requiring emergency resectional surgery (QoE
B).
Statement 4.10 In complex perianal fistulizing disease,
infliximab or adalimumab can be used as a first-line
therapy in combination with azathioprine following ad-
equate surgical drainage if indicated. A combination of
ciprofloxacin and anti-TNF improves short-term out-
comes (QoE A).
b) The role of nutritional support
Statement 4.11 Preoperative nutritional support is
mandatory in severely undernourished patients (QoE A).
Statement 4.12 Total parenteral nutrition should be re-
served for nutritionally deficient IBD patients unable to
tolerate enteral nutrition and when the enteral route is
contraindicated, in critically ill patients presenting with
signs of shock, intestinal ischemia, high output fistula,
and/or severe intestinal hemorrhage (QoE B).
Statement 4.13 Total parenteral nutrition is the mode
of choice when emergency surgery is needed for compli-
cated IBD (QoE A).
Recommendations We recommend evaluating medical
treatment in IBD patients presenting with acute abdom-
inal pain and disease activity in a multidisciplinary ap-
proach (strong recommendation based on low-level
evidence 1C).
We recommend not routinely administrating antibi-
otics in IBD patients but only in the presence of super-
infection, intra-abdominal abscesses, and sepsis (strong
recommendation based on high-level evidence 1A)
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We recommend administering antibiotics according to
the epidemiology and resistance of the setting in a dur-
ation that depends on the patient’s clinical and biochem-
ical findings. Antifungals should be reserved for high-
risk patients such as those with bowel perforation and
recent steroid treatment (strong recommendation based
on high-level evidence 1A).
We recommend administering as soon as possible ven-
ous thromboembolism prophylaxis with LMWH for the
high risk of thrombotic events related to complicated
IBD and the emergency setting (strong recommendation
based on high-level evidence 1A).
We recommend weaning off steroids (wean preopera-
tively, ideally 4 weeks) and stopping immunomodulators
associated with anti-TNF-α agents before surgery, as
soon as possible to decrease the risk of postoperative
complications, in accordance with a gastroenterologist
(strong recommendation based on moderate level evi-
dence 1B).
We recommend administering nutritional support
(parenteral or enteral, according to GI function and in
conjunction with a dietician/nutrition team) in IBD pa-
tients as soon as possible (strong recommendation based
on moderate level evidence 1B).
Summary of evidence and discussion The manage-
ment of IBD in an emergency setting is very challenging.
Early surgical management is correlated with extended
intestinal resection, high stoma rate, and high risk of
postoperative complications. Preoperative optimization
of the patient, PD, and delayed surgery are associated
with decreased risk of complications and length of post-
operative stay. Medical treatment should be discussed in
a multidisciplinary team. In the management of patients
with CD presenting with an intra-abdominal abscess,
few studies have addressed medical treatment alone
(without percutaneous or surgical drainage) as the pri-
mary approach, and all available reports are retrospective
or observational studies. According to available data,
only abscesses smaller than 3 cm could be treated with
antibiotics alone without PD, but it is not clear how to
select patients for this therapeutic approach and for how
many days to administer antibiotics, with high (37 to
50%) recurrence rates [45].
Following abscess drainage, the preferred CD medical
treatment option is anti-TNF therapy in addition to on-
going antibiotic treatment [46]. There are no random-
ized studies in the literature to clarify whether
percutaneous or surgical drainage should always be
followed by a delayed resection, although most case
series favor a delayed elective resection.
In case of an ileal stenosis, a delayed resection should
be considered and it is preferred to de-escalate
corticosteroids prior to surgery in order to reduce the
risk of post-operative complications [47].
The available literature on the use of biologic therapy
before urgent surgery with anti-TNF-α agents, anti-
integrin therapy, and anti-interleukin therapy is controver-
sial. Biologic agents can induce and maintain clinical re-
mission, heal the mucosa, and change the natural course
of the disease, if used in a timely fashion, avoiding disease
progression towards stenosis and fistula formation [48].
The PUCCINI trial [49] is based on a high level of evi-
dence due to the strict protocol followed in collecting data
prospectively, and its results demonstrated no effect of
anti-TNFs on postoperative complications.
Other factors that can affect postoperative complications
in intestinal resections in patients with CD are previous use
of steroids, impaired nutritional status, and an unfavorable
abdominal environment. Usually, most patients with surgi-
cal indication in CD are already using biological agents,
and more than one of these factors can also be present.
Therefore, in malnourished patients, with previous steroids
and/or anemia, the surgical approach can be affected.
In conclusion, direct cause–effect relationship of bio-
logics alone leading to increased rates of complications
was not demonstrated and different studies results are
controversial [50].
If an urgent surgical exploration is needed, it is ex-
tremely important to check concomitant use of steroids,
phenotype of the disease, and current nutritional status,
in order to establish the surgical plan.
The influence of nutritional status on postoperative
morbidity and mortality has been well documented in
both retrospective and prospective studies. Poor pre-
operative nutritional status has been linked consistently
to an increase in post-operative complications and
poorer surgical outcome.
Malnutrition is an independent risk factor for adverse
postoperative outcomes and affects up to 70% of the
IBD population. Malnutrition can occur in UC but is a
more common problem in CD since CD can affect any
part of the GI tract and UC is restricted to the large
bowel, which has few direct malabsorptive effects. Nutri-
tional complications occur in 20 to 85% of patients with
CD. This specific condition becomes more serious dur-
ing the active phase of CD, which is associated with de-
creased food intake, intestinal absorption dysfunction,
drug side effects, and active inflammation [51].
Defining malnutrition is difficult, especially in patients
with IBD, and a gold-standard test of malnutrition has
not been identified.
The European Society for clinical nutrition and metab-
olism (ESPEN) reported that serum albumin of <3 g/dl,
BMI < 18.5 kg/m2, and weight loss > 10–15% within 6
months are the best indicators of severe malnutrition in
CD [52].
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Parenteral nutrition should be reserved for nutrition-
ally deficient IBD patients unable to tolerate enteral nu-
trition and when the enteral route is contraindicated in
patients presenting with severe shock, intestinal ische-
mia, high output fistula, and/or severe intestinal
hemorrhage [53, 54].
Preoperative nutrition supplementation reduces post-
operative complications in patients with CD, in particu-
lar, enteral nutrition. In a recent meta-analysis (3
prospective and 2 retrospective studies including 1111
CD patients), it was reported that the rate of postopera-
tive complications in the group receiving preoperative
nutritional (enteral or total parenteral nutrition) support
was 20.0% compared with 61.3% in the group who had
standard care without nutritional support [OR=0.26,
95% confidence interval (CI): 0.07–0.99, P<0.001]. Post-
operative complications occurred in 15.0% of patients
in the group who received preoperative total paren-
teral nutrition compared with 24.4% in the group
who did not (OR=0.65, 95% CI: 0.23–1.88, P=0.43).
Postoperative complications occurred in 21.9% in the
group who received preoperative enteral nutrition
compared with 73.2% in the group that did not re-
ceived preoperative enteral nutrition (OR=0.09, 95%
CI: 0.06–0.13, P<0.001) [55].
Exclusively enteral nutrition is feasible in CD pa-
tients presenting with non-radiologically drainable ab-
dominal abscesses. It is associated with a reduction in
surgical rate, optimized preoperative condition, and
improved postoperative outcomes in this specific
group of patients [56].
Concerning the role of a medical treatment to avoid or
postpone surgery, most patients with UC presenting
with an ongoing flare in an emergency setting could be
treated with intravenous corticosteroids.
In this group of patients, when the checked
hemodynamic status is stable, the first step in the diag-
nostic process includes confirming disease activity with
a flexible sigmoidoscopy and ruling out intestinal patho-
gens including Clostridium difficile and CMV. At this
point, it is possible to decide on rescue therapy.
Patients with significant systemic toxicity, as evidenced
by severe weight loss, fever, tachycardia, high inflammatory
markers, and persisting abdominal pain, should be evalu-
ated for colectomy. If a medical rescue therapy is consid-
ered appropriate, IV corticosteroids are administrated. A
systematic review of 32 trials of steroid therapy for acute se-
vere colitis, involving 1991 patients from 1974–2006, re-
ported an overall response to steroids of 67% [95% CI 65–
69%] [57]. A colectomy was carried out in 29%.
In case of insufficient response to IV corticosteroids,
an early (day 3) assessment should take place and subse-
quent therapy with either infliximab (IFX) (5 mg/kg) or
ciclosporin (2 mg/kg/day) should be considered, along
with the possibility of surgery. Both medical therapies
are potent for inducing remission in this subgroup of pa-
tients with comparable outcomes. The open-label CYSIF
trial randomized 111 thiopurine-naive patients with se-
vere colitis despite 5 days of IV steroids, to IV ciclos-
porin 2 mg/kg/day for 8 days followed by 4 mg/kg/day
oral therapy, or infliximab 5 mg/kg at weeks 0, 2, and 6
[55]. All responders at day 7 received oral azathioprine
and tapered steroids from day 8. Approximately 85% pa-
tients in both groups responded to treatment by day 7.
Treatment failure at day 98 (the primary endpoint) was
reported in 60% patients in the ciclosporin arm com-
pared with 54% patients in the IFX arm. The colectomy
rate by day 98 in the ciclosporin vs the infliximab group
was 18% vs 21% [P = 0.66] [58].
If a surgical procedure is needed, then subsequent ster-
oid withdrawal is mandatory [59]. Antibiotics should not
be routinely administered. Controlled trials of oral or IV
metronidazole, tobramycin, ciprofloxacin, or vancomycin
in acute UC have shown no consistent benefit in addition
to conventional therapy [60–62]. In the treatment of com-
plex peri-anal fistulae due to CD an initial abscess drain-
age and seton placement, according to the symptoms and
complexity of the fistula and anti-TNF treatment includ-
ing infliximab or adalimumab can reduce fistula drainage
and induce fistula closure [63, 64].
Antibiotics such as a combination of ciprofloxacin and
metronidazole can be added to enhance this effect, but
this will only aid in improving short-term clinical out-
comes [64]. To enhance the effect of anti-TNF in com-
plex fistulizing disease, combination of anti-TNF
treatment with thiopurines should be considered.
Zangenberg et al. [59] carried out a systematic review
to identify clear recommendations for the preoperative
medical management of patients with IBD, in particular
those with CD.
The analysis of the literature showed that before elect-
ive surgery:
 Steroid withdrawal (wean preoperatively, ideally 4
weeks unless an emergency) is recommended while
steroid stress dose is not recommended;
 Thiopurines’ administration appears to be safe, but
it may be prudent to plan the procedure remotely
from the last dose of an anti-TNF agent;
 Nutritional risk screening is recommended to unveil
and correct any malnutrition;
 Venous thromboprophylaxis prior to surgery is well
supported by evidence while extended 4-week
prophylaxis needs further research but is likely to be
beneficial;
 Percutaneous us or CT-guided drainage for intra-
abdominal abscesses is recommended with a consid-
erable risk of recurrence;
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 Smoking cessation can be beneficial for wound
healing, as well as reducing the risk of disease
recurrence in CD.
Q.5: What are the indications for emergency surgery in
patients presenting with complications related to IBD?
Urgent surgical treatment is to be considered in the fol-
lowing clinical setting:
1) Acute severe ulcerative colitis
Statement 5.1.1 If a patient’s condition does not im-
prove or deteriorates within 48 to 72 h from initiation of
medical therapy, a second-line therapy or surgery should
be considered and discussed by the emergency surgeon
and the gastroenterologist in acute severe ulcerative col-
itis (QoE C).
Statement 5.1.2 In the event of surgical complications
such as free perforation, life-threatening hemorrhage (un-
stable patients), or generalized peritonitis, immediate
surgery is recommended in acute severe ulcerative col-
itis (QoE B).
Statement 5.1.3 In case of no improvement with a
second-line therapy, in discussion with a gastroenterolo-
gist, surgery is recommended in acute severe ulcerative
colitis (QoE C).
Statement 5.1.4 Subtotal colectomy with ileostomy is a
safe and effective treatment for patients requiring emer-
gency surgery for acute severe ulcerative colitis present-
ing with massive colorectal hemorrage (QoE B).
Recommendations We suggest evaluating all
hemodynamically stable patients presenting with acute
severe ulcerative colitis in a multidisciplinary ap-
proach with the gastroenterologist to decide on options
for initial medical treatment (weak recommendation
based on low-level evidence 2C).
We recommend performing emergency surgical ex-
ploration in hemodynamically unstable patients, accord-
ing to damage control principles and in patients with
colonic perforation. A Subtotal colectomy with ileos-
tomy in acute severe ulcerative colitis is the surgical
treatment of choice in patients presenting massive colo-
rectal haemorrhage or non-responders to medical treat-
ment (strong recommendation based on high-level
evidence 1A).
Summary of evidence and discussion According to the
diagnostic criteria of Truelove and Witts for UC severity
classification, acute severe colitis affects 5 to 15% of pa-
tients with UC and is characterized as colitis with bloody
stool frequency ≥ 6/day and a tachycardia (>90bpm), or
temperature >37.8°C, or anemia (hemoglobin 10.5g/dL),
or an elevated ESR (>30mm/h) (only one additional cri-
terion in addition to the bloody stool frequency ≥6/day
is needed to define a severe attack). Endoscopic criteria
for severe colitis include a hemorrhagic mucosa with
deep ulceration, mucosal detachment on the edge of
these ulcerations and well-like ulceration, all of which
can be assessed at flexible sigmoidoscopy [65].
There are some controversies regarding the indica-
tions for surgery in case of severe acute colitis, and
the determination of the correct time for surgery is
still a matter of debate. It is well known that the ma-
jority with severe acute colitis will respond to medical
therapy: in 2007, Turner et al. [57] conducted a sys-
tematic review including 32 clinical trials analyzing
the response to steroid therapy in severe UC and
found that the response rate to steroids is 66% and
34% of patients required colectomy within a short
period of time. This study has some limitations, such
as the time period of the included studies (1974–
2006) and the wide heterogeneity among included co-
horts of patients, but interestingly found a small re-
duction in colectomy rates in the studies that
reassessed the need for colectomy after 2 weeks of
medical therapy versus those who did it within 2
weeks. Furthermore, the introduction of biologic ther-
apy opened new perspectives for salvage therapy in
steroid-refractory patients and some studies demon-
strated that up to 80% of patients with acute severe
colitis resistant to steroid therapy could respond to
biologic therapy, thus avoiding an emergent colec-
tomy [66, 67]. Post-operative morbidity is higher after
emergency surgery when compared with elective sur-
gery, for both UC and CD [68], suggesting that the
increased use of rescue therapy may contribute to re-
ducing emergency surgical interventions and improve
outcome [69]. On the other hand, there is evidence
to suggest that both a delay in surgery [70, 71] and
prolonged intravenous immunosuppressive therapy are
associated with increased morbidity and mortality fol-
lowing subsequent surgery [72, 73]. Based on these
results, it seems reasonable to suggest a tailored ap-
proach to the patient with acute severe colitis and an
attempt at initial conservative management with bowel
rest, parenteral nutrition, parenteral steroids, and broad-
spectrum antibiotics. The patient must be monitored
closely for any signs of progressive deterioration, such as
worsening pain or tenderness, progressive leukocytosis,
fever, tachycardia, or hypotension. For steroid refractory
disease, surgical options or therapeutic alternatives for res-
cue therapy should be considered early (on or around day
3 of corticosteroid therapy) by a multidisciplinary team
that includes both a surgeon and gastroenterologist.
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2) Toxic megacolon
Statement 5.2.1 In patients presenting with toxic mega-
colon complicated by perforation, massive bleeding (un-
stable patients), clinical deterioration, and signs of
shock, surgery is mandatory (QoE A).
Statement 5.2.2 In patients presenting with toxic mega-
colon, showing no clinical improvement and biological
signs of deterioration after 24–48 h of medical treat-
ment, surgery is mandatory (QoE B).
Recommendation We recommend not delaying surgery
in critically ill patients presenting with toxic megacolon
(strong recommendation based on moderate -level evi-
dence 1C).
Summary of evidence and discussion Toxic megacolon
is a rare but severe and potentially fatal complication of
colonic inflammation.
Its main characteristics are as follows [74]:
 Radiographic evidence of total or segmental colonic
distention of > 6 cm
 Presence of systemic toxicity
 Inflammatory (or infectious) etiology.
In order to avoid colectomy, medical treatment should
be carried out aggressively and in a timely fashion (ste-
roids, fluids, transfusions, etc.) and the correct timing
for surgery is still controversial. In fact, while some evi-
dence suggests that the initial medical treatment obvi-
ates the need for surgery in about 50% of patients [75],
there is a significant body of literature that highlights
how a delay in surgical intervention carries the risk of
colonic perforation and abdominal compartment syn-
drome, thus increasing the mortality rate [76, 77]. For
these reasons, management of toxic megacolon requires
coordination between medical and surgical services with
aggressive attempts at medical therapy and early surgical
intervention in the absence of improvement, develop-
ment of complications, or deterioration. Frequent re-
evaluations must be performed until the patient’s condi-
tion has clearly improved or until there is evidence of
deterioration, in which case urgent surgery is indicated.
Persistent fever after 48–72 h of steroid therapy should
raise the possibility of local perforation or abscess. Free
perforation, massive hemorrhage, increasing transfusion
requirements, increasing signs of toxicity, and progres-
sion of colonic dilatation are indications for an urgent
operation.
Unlike colonic obstruction, in which cecal dilation
with perforation is a concern, the transverse colon is the
area of greatest concern in toxic megacolon. Perforation
in patients with toxic megacolon is associated with a
high mortality rate (27–57%), regardless of whether the
perforation is contained or free [78–80].
3) Uncontrolled gastrointestinal bleeding
Statement 5.3.1 Pre-operative localization of the bleed-
ing site, with the aim of excluding an upper gastrointes-
tinal or an anorectal bleeding will allow better planning
of the surgical strategy (QoE C).
Statement 5.3.2 An upper and lower GI endoscopy
should be the initial diagnostic procedure for nearly all
stable patients presenting with acute gastro-intestinal
bleeding (QoE C).
Statement 5.3.3 Computed tomography angiography
should be performed in patients with ongoing bleeding
who are hemodynamically stable after resuscitation
(QoE C).
Statement 5.3.4 Surgical treatment is recommended in
patients with life-threatening bleeding and persistent
hemodynamic instability and in patients with acute se-
vere ulcerative colitis non-responders to medical treat-
ment presenting with massive colorectal
hemorrhage (QoE B).
Statement 5.3.5 Significant recurrent gastrointes-
tinal bleeding could be an indication for urgent surgery
(QoE C).
Recommendations We recommend performing imme-
diate surgery in unstable patients presenting with
hemorrhagic shock, and non responders to resuscitation.
An intraoperative ileoscopy, if available, could be useful
in localizing the bleeding source in patients with Crohn’s
disease. In patients presenting with acute severe ulcera-
tive colitis and refractory hemorrhage, non-responders
to medical treatment, the surgical treatment of choice is
a subtotal colectomy with ileostomy, if skills are present
(strong recommendation based on low-level evidence
1C).
We suggest evaluating hemodynamically stable IBD pa-
tients presenting a gastrointestinal bleeding at first with
a sigmoidoscopy and an esophagogastroduodenoscopy
(weak recommendation based on low-level evidence 2C).
Summary of evidence and discussion Gastrointestinal
bleeding is a common complication in patients with UC
or CD and is caused by inflammation/ulceration of the
bowel. Usually, the bleeding resolves with medical treat-
ment and rarely it requires an immediate surgical
procedure.
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Medical treatment includes patients with
hemodynamic instability and/or suspected ongoing
bleeding receiving intravenous fluid/blood product re-
suscitation with the goal of normalization of blood pres-
sure and heart rate prior to endoscopic evaluation/
intervention. Packed red blood cells should be transfused
to maintain the hemoglobin above 7g/dL. A threshold of
9g/dL should be considered in patients with massive
bleeding, significant comorbidities (especially cardiovas-
cular ischemia) or possible delay in receiving therapeutic
interventions [81].
Massive, life-threatening lower gastrointestinal bleed-
ing is uncommon in patients with IBD and occurs in less
than 6% of cases [82]. Because of the low incidence of
severe hemorrhage in IBD, a limited number of studies
are available to guide management.
In IBD patients, bleeding has different features de-
pending on the underlying disease. In UC, the bleeding
typically occurs in patients with pancolitis from diffuse
areas of mucosal ulceration. In CD, however, the bleed-
ing most often is a result of focal erosion into an intes-
tinal vessel, and this could include the small bowel.
In UC, the endoscopic assessment and treatment of
the bleeding source that could be massive because of the
diffuse nature of colonic inflammation is rarely possible.
In CD, which is often a segmental disease, it is useful to
try to localize the source of bleeding preoperatively to
avoid surgery or an extensive intestinal resection, even
more so severe bleeding in a patient with CD could be
due to an associated condition, such as gastritis or peptic
ulcer disease, or multiple segments of GI tract could be
involved in the bleeding and this could be a diagnostic
and therapeutic challenge for the endoscopist, with a
high risk of re-bleeding.
The hemodynamic status of the patient presenting
with hematemesis or massive melena or bright red rectal
bleeding has to be assessed: the patient has to be resusci-
tated and stabilized, and a nasogastric tube is inserted to
protect the airway and decompress the stomach. In a
stable patient, a gastroscopy could be required to rule
out an upper gastrointestinal bleeding. If a lower gastro-
intestinal source is suspected then one should consider
sigmoidoscopy or colonoscopy.
The clinical significance of performing contrast-
enhanced CT before colonoscopy has been examined in
recent years. In a retrospective study of acute LGIB,
Nagata et al. reported that the detection rate for vascular
lesions was higher for colonoscopy following CT than
for colonoscopy alone (35.7% vs 20.6%, P = 0.01), leading
to more endoscopic examinations (34.9% vs 13.4%, P <
0.01) [83].
In patients with IBD who are bleeding, the role of
angiography and of angioembolization is not yet clear:
the few studies available in the literature are case reports
and suggest that angiography/angioembolization could
be feasible in stable patients, but further studies are
needed to better define outcomes in emergency setting.
The major advantage of angiography and embolization
is that it can control severe bleeding without bowel
preparation. A systematic review reported that super-
selective angiographic embolization achieves immediate
hemostasis in 40–100% of diverticular bleeding with oc-
casional rebleeding (15%) [84]. The disadvantages of
angiography and embolization include the requirement
for active bleeding and the risk of bowel ischemia and
the administration of IV contrast. The rate of bowel is-
chemia following embolization was 1–4% in recent stud-
ies [85, 86]. Angiography localizes the bleeding source in
24–70% of cases [87]. Angiography requires blood loss
rates > 0.5 mL/min to localize a bleeding site [88].
Moreover, CT angiography may be useful as a nonin-
vasive diagnostic tool prior to angiography, because it is
more sensitive and identifies bleeding at rates of 0.3 mL/
min [89]. Other methods of localization include the use
of a nuclear medicine labeled red cell scans if bleeding is
not detected by angiography [65].
Once the source is known, the decision to perform a
surgical urgent procedure depends on bleeding source
itself, the hemodynamic condition of the patient and on
the availability/feasibility of less invasive therapeutic op-
tions (i.e., endoscopy or angiography) [90].
If the patient is unstable, even after significant resusci-
tation, a surgical exploration is mandatory. In clinical
practice, surgery is indicated for patients who demon-
strate continued hemorrhage despite resuscitation or
have other indications for resection of diseased bowel
[91].
Significant bleeding is a rare event in Crohn’s disease,
and all common causes of upper and lower gastrointes-
tinal bleeding should be assessed; when a surgical ex-
ploration is required, it is recommended to perform an
intra-operative ileoscopy to find the source of bleeding if
the source has not been identified pre-operatively. All ef-
forts to identify the bleeding source should be made pre-
operatively.
In case of acute severe ulcerative colitis, the bleeding
could involve all the colon mucosa, and the surgical
treatment of choice is a subtotal colectomy with ileos-
tomy, to decrease the risk of recurrent bleeding, but it is
important to have performed a flexible sigmoidoscopy to
make sure there is no significant bleeding source in the
rectum.
4) Free perforation
Recommendation We recommend performing surgical
exploration in the presence of radiological signs of pneu-
moperitoneum and free fluid within the peritoneal cavity
De Simone et al. World Journal of Emergency Surgery           (2021) 16:23 Page 19 of 27
in acutely unwell patients presenting with complicated
Crohn's disease or acute severe ulcerative colitis (strong
recommendation based on low-level evidence 1C).
Summary of evidence and discussion Free peritoneal
perforation in inflammatory bowel disease is a rare con-
dition, with few cases reported in the literature. It occurs
in 1–3% of Crohn’s disease patients as a first manifest-
ation or in the course of the disease [92], and it is more
frequent in severe acute ulcerative colitis. Perforation is
considered a serious and potentially life-threatening
event and is one of the main indications for emergency
surgical intervention. Free perforation is the indication
for surgery in up to 16% of the cases of complicated IBD
[93, 94]. The site of perforation is usually located in the
colon in cases of UC, while patients with CD can present
with perforation of either the small or large bowel. Free
perforation is an absolute indication for emergency sur-
gery, even though the evidence available in the literature
is scarce, but delayed surgery is correlated with high
mortality and morbidity in patients with IBD.
5) Intestinal obstruction
Statement 5.5.1 Surgery is mandatory for symptomatic
strictures that do not respond to medical therapy and
are not amenable to endoscopic dilatation (QoE C).
Statement 5.5.2 Any colorectal stricture should be
assessed with endoscopic biopsies to ensure the absence
of malignancy (QoE C).
Recommendation We recommend performing surgery
in patients presenting with bowel obstruction because of
fibrotic or medically resistant stenosis (strong recom-
mendation based on low-level evidence 1C).
Summary of evidence and discussion Small bowel ob-
struction is the most common complication requiring
elective surgery in CD and affects up to 54% of patients
[95]. Strictures complicating CD usually affect the small
bowel but could arise anywhere in the GI tract and
could be divided into inflammatory or fibrostenotic. It is
often difficult to distinguish whether the obstruction is
caused primarily by inflammation or fibrostenosis. Pa-
tients with inflammatory disease deserve a trial of medi-
cations aimed at reducing inflammation. Conversely,
patients with symptomatic fibrostenotic disease and ob-
struction require an interventional approach, either sur-
gical or endoscopic.
Endoscopic balloon dilation has proven successful in
the management of primary intestinal strictures or anas-
tomotic strictures in CD. For fibrotic strictures, endo-
scopic balloon dilation has a technical success rate of 89
to 92%, with 70 to 81% patients experiencing short-term
relief of symptoms [96]. Long-term results are less im-
pressive, with 73.5% of patients requiring a repeat dila-
tion and 43% requiring surgical intervention within 2
years [97].
Endoscopic stricturotomy is an evolving, novel therapy
for which only few short-term retrospective studies exist
to demonstrate its safety and efficacy compared with
endoscopic balloon dilation or ileocolic resection [95].
Large bowel strictures, especially in UC, should raise
high concern for malignancy [98]. When required to
perform an emergent colectomy, oncologic principles
should be followed. Patients with small bowel stenosis
mainly due to inflammation may improve with medical
treatment such as steroids. In patients that do not show
improvement with medical treatments, suspect stenosis
due to fibrosis, and consider radiological investigation
with CT or MR enterography and the possibility of
endoscopic dilation on the basis of the length and site of
the stenosis, the number of stenotic sites, and the pres-
ence of ulcers.
Surgery is warranted for small bowel CD stenosis that
causes an intestinal obstruction with potential impend-
ing perforation, with long or multiple strictures, when
the stricture is not endoscopically accessible and when
medical and/or endoscopic treatment fails to adequately
improve the patient’s symptoms or when there is con-
cern about concomitant malignancy.
Q.6: Which surgical approach is recommended for
complicated IBD in the emergency setting?
1) Emergency surgery for ulcerative colitis
Statement 6.1.1 In the setting of free perforation and
generalized peritonitis or toxic megacolon, in
hemodynamically unstable patient, an open approach is
recommended (QoE C).
Statement 6.1.2 Both open and laparoscopic approaches
are otherwise appropriate in the emergency setting, ac-
cording to patient's hemodynamic stability and signs of
sepsis in complicated ulcerative colitis (QoE C).
Statement 6.1.3 A laparoscopic approach (multi-port or
in a single incision), if local expertise allows, may reduce
length of stay and morbidity in hemodynamically
stable patients presenting with complicated ulcerative
colitis (QoE C).
2) Emergency surgery for Crohn’s disease
Clinical scenarios:
a) Intestinal obstruction Statement 6.2.1
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If emergency surgery is indicated, a laparoscopic ap-
proach to adhesiolysis and bowel resection is recom-
mended if appropriate expertise exists, with care taken
to avoid iatrogenic bowel injury in patients presenting
with intestinal obstruction for Crohn's disease (QoE C).
b) Bleeding Statement 6.2.2
If the patient presenting with gastrointestinal bleeding
in Crohn's disease is hemodynamically stable and endo-
scopic and/or interventional radiology measures have
been unsuccessful, then a surgical exploration in a lap-
aroscopic (multi-port or in single incision) approach is
recommended (QoE C).
Statement 6.2.3
If the patient presenting with gastrointestinal bleeding
in Crohn's disease is hemodynamically unstable and
endoscopic and/or interventional radiology procedures
have been unsuccessful, then a surgical exploration in
an open approach is recommended to reduce operating
time (QoE C).
c) Free perforation and purulent/fecal peritonitis
Statement 6.2.4
A laparoscopic approach with resection, lavage and
stoma is suggested in hemodynamically stable patients
presenting with perforation and peritonitis in Crohn's
disease, to avoid complications associated with anasto-
motic leak (QoE C).
Statement 6.2.5
If there is hemodynamic stability and only localized
contamination, an anastomosis may be considered but
other factors will also need to be considered (QoE C).
Statement 6.2.6
If evidence of severe sepsis/septic shock, damage con-
trol surgery may be considered, with resection, stapled
off bowel ends, and temporary closure (laparostomy)
with return to theater in 24–48 h for a second look,
washout, and consideration of stoma vs anastomosis
(QoE C).
d) Crohn’s colitis Statement 6.2.7
Subtotal colectomy and ileostomy are the emergency
operations of choice for severe acute and refractory colitis,
with open and laparoscopic approaches appropriate in the
emergency setting according to patient's hemodynamic
stability (QoE C).
Statement 6.2.8
A laparoscopic approach, if local expertise allows, may
reduce length of hospital stay and risk of infectious com-
plications (QoE C).
Statement 6.2.9
There is insufficient evidence to recommend SILS or
robotic surgery in the emergency setting (QoE C).
3) Anastomotic considerations in emergency surgery for
Crohn’s disease
Statement 6.3.1
If a patient in the emergency setting has 2 or more risk
factors for anastomotic complications (such as discussed
in the text), then a stoma should be formed following re-
section (QoE C).
Statement 6.3.2
If a decision to anastomose has been made, there is no
evidence to suggest that one type of anastomosis (sta-
pled vs hand sewn) is superior to the other in terms of
complication rates or recurrence, and the decision can
be left to surgeon preference (QoE C).
Recommendations
We recommend performing a surgical exploration by
laparotomy in a hemodynamically unstable patient pre-
senting with complications related to IBD such as per-
foration and severe peritonitis, massive intestinal
bleeding, obstruction, toxic megacolon, severe colitis
non responder to medical treatment, taking into consid-
eration damage control surgery principles with or with-
out an open abdomen (strong recommendation based
on low-level evidence 1C).
We recommend performing a laparoscopic approach
in hemodynamically stable patients presenting complica-
tions related to IBD, when skills are available, in order
to decrease morbidity and length of hospital stay (strong
recommendation based on low-level evidence 1C).
We recommend performing a subtotal colectomy with
ileostomy in patients presenting with acute severe
refracrory colitis, non responders to medical treatment,
in a laparoscopic or open approach according to pa-
tient’s hemodynamic stability (Strong recommendation
based on low level evidence 1C). We suggest considering
an (stapled or hand sewn) anastomosis in
hemodynamically stable patients with Crohn's dis-
ease who have good pre-existing nutritional status and
who are taking no steroids or other immunosuppression
and presenting with no bowel vascular compromise and
only localized peritonitis. A defunctioning stoma should
also be considered in the emergency setting (weak rec-
ommendation based on low-level evidence 2C).
Summary of evidence and discussion
Surgical treatment can be particularly challenging
when patients with IBD present as an emergency, as they
are often much more unwell than when being consid-
ered for elective intervention. Moreover, the surgical op-
tions may be more limited and there may also be less
time for full multidisciplinary involvement in the deci-
sion making process, especially in critically ill patients.
In addition, many centers will have an emergency surgical
on-call rota that is staffed with surgeons whose main spe-
cialist elective practice is not in IBD surgery. Therefore, it
is necessary to be aware of the principles of emergency
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operative surgery for patients presenting acutely with the
complications or sequelae of UC and CD.
Emergency surgery for Ulcerative colitis
The indications for emergency surgery in ulcerative col-
itis include medically resistant disease, bleeding, toxic
megacolon, and perforation [96, 99]. Open and laparo-
scopic approaches may be considered in the emergency
setting, according to availability of trained local expertise.
There is a role for open surgery [100–103]. An open
approach is likely to be favored in the setting of a perfor-
ation, where a faster operation is required to allow the
patient to have their source control surgery in a timely
fashion and to be cared for post-operatively in the ICU
as quickly as possible. In addition, toxic megacolon,
which is now thankfully uncommon, may prove particu-
larly challenging in terms of handling the bowel laparo-
scopically without perforation, and so open surgery is
again recommended.
Otherwise, laparoscopic surgery has been shown to
lead to a reduction in length of stay and infectious com-
plications in the emergency setting [104–106]. The exist-
ing data relate to multiport laparoscopic surgery, and as
such, this would be recommended over a single port ap-
proach in the emergency setting, with no data available
to support the use of a robotic approach.
Emergency surgery for Crohn’s disease
Indications for emergency abdominal surgery in the
setting of Crohn’s disease include bowel obstruction,
perforation, and bleeding [96, 99]. Management of pa-
tients with an intra-abdominal abscess has been dealt
with elsewhere in this guideline.
Up to 16% of patients with Crohn’s disease will
present with a bowel perforation [107]. Management de-
cisions are often complex and will need to be made
around mode of surgical access, decision for anasto-
mosis, and if so, using which anastomotic technique.
Bowel resection is generally required in the emergency
setting, with the requirement for strictureplasty being
more common in the elective setting. The type of resec-
tion needed will be according to the disease site, and this
may be a small bowel resection, ileocecal resection, or
colonic resection, generally subtotal colectomy.
In terms of mode of access, for the patient with bowel ob-
struction due to non-active stricturing disease or adhesions,
a laparoscopic approach is preferred, according to local ex-
pertise, as there is evidence for reduced length of stay and
fewer complications [108, 109]. Great care is needed on es-
tablishing pneumoperitoneum, as the bowel will be dis-
tended, and as such, an open port insertion technique
should be used. Available data relate to multi-port laparo-
scopic approach, as opposed to single-port, and there are
no data to support a robotic approach in this setting.
An open approach remains preferable in the setting of
bleeding with hemodynamic instability where endoscopic
and interventional radiology techniques have not been
successful, and in a patient with a free perforation. When
a patient with a free perforation has severe sepsis or septic
shock, and associated significant peritoneal contamin-
ation, it may be preferable to perform damage limitation
surgery in the form of bowel resection with stapled off
bowel ends, peritoneal lavage, laparostomy, and rapid re-
turn to ICU for on-going care, with a planned second look
laparotomy 24–48 h later with further bowel inspection,
peritoneal lavage, abdominal closure, and consideration of
stoma formation versus anastomosis.
Anastomosis decision making in Crohn’s disease in
the emergency setting.
In the emergency setting, the decision whether to per-
form a primary anastomosis following resection for
Crohn’s disease can be challenging, and there are also
considerations of whether a particular anastomotic tech-
nique may be preferable if so.
It is imperative to consider the clinical state and pres-
entation of the patient, as well as the indication for sur-
gery, when thinking about whether an anastomosis may
be appropriate in the emergency setting. Factors to con-
sider when contemplating anastomosis include the
following:
 Patient factors: e.g., sepsis, degree of peritoneal
contamination (local only vs widespread),
hemodynamic stability, need for inotropes,
nutrition/albumin, abscess, immunosuppression
(e.g., steroids, timing of recent anti-TNF treatment),
smoking
 Disease factors: fistulising/perforating vs stenotic,
proximal jejunal vs ileal
If a patient has 2 or more risk factors in the emergency
setting, then a resection with stoma should be performed,
rather than an anastomosis. A stoma following resection
may still be an appropriate option when only one risk fac-
tor is present. If an anastomosis is performed, consider-
ation should be given to a defunctioning stoma.
If an anastomosis (usually small bowel or ileocolic) is to
be performed, then in general, the options to consider will
include the configuration (end-to-end vs side-to-side) and
material (stapled vs suture) used. Overall, in the specific
setting of IBD surgery, there is no evidence for superiority
of any one technique over the other in terms of complica-
tion rates or recurrence [110–112]. Therefore, the deci-
sion can generally be left to surgeon preference.
If a stapled anastomosis is being performed, consider-
ation should be given to performing this in an isoperis-
taltic configuration, in order to allow easier neo-terminal
ileal intubation at subsequent surveillance colonoscopy.
If there is chronically thickened small bowel in the setting
of a long-standing bowel obstruction, consideration should
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be given to performing a hand-sewn anastomosis as the
stapler may not function adequately in this setting where
the bowel wall is very thickened and edematous [112].
Data for the newer Kono-S small bowel anastomotic
configuration [113], which is a hand sewn technique that
leads to a wide lumen with mesenteric exclusion, are
confined to the elective setting and as such, would not
be recommended for emergency cases at present.
In Crohn’s colitis, the indications for emergency sur-
gery are as for ulcerative colitis, including medically re-
sistant disease, bleeding, toxic megacolon, and
perforation and may also include large bowel obstruction
if there is a stricture present. Open and laparoscopic ap-
proaches are appropriate in the emergency setting, ac-
cording to local expertise.
Q.7: How to manage perianal sepsis in the emergency
setting?
Statement 7.1
An acute abscess should be adequately drained under
general anesthetic, with no routine requirement for
wound packing (QoE C).
Statement 7.2
No active attempt should be made to find an associated
anal fistula at the initial abscess presentation (QoE C).
Statement 7.3
If an obvious fistula exists (without probing), the fistula
should not be laid open and a loose draining seton
should be inserted (QoE C).
Statement 7.4
There is no role for any additional surgical fistula treat-
ment modality in the emergency treatment of Crohn’s
perianal sepsis (QoE C).
Statement 7.5
An assessment of the rectum should be made at the time
of abscess drainage, to assess for signs of proctitis (QoE
C).
Recommendation
We recommend performing adequate surgical drainage
of perianal abscess in Crohn's disease without searching
for an associated fistula (strong recommendation based
on low-level evidence 1C).
Summary of evidence and discussion
Around 1 in 3 patients with CD will develop perianal
manifestations of the disease [114, 115], which will in-
clude the risk of perianal abscess and fistula. When pre-
senting with an acute perianal or ischiorectal abscess,
the main principle of surgical intervention is to perform
adequate drainage, and this will likely require a general
anesthetic in most cases.
In the acute setting, it can be difficult to find an
underlying fistula with significant induration and sepsis
present, and so no active attempt should be made to find
an associated fistula and minimal tissue disruption/de-
struction should occur. Over-vigorous attempts to probe
for a fistula at emergency surgery may lead to an iatro-
genic track and internal opening, which will add great
complexity to the on-going management of the patient’s
perianal disease and greatly increase the risk of non-
healing.
If there is a deep cavity evident, consideration may be
given to short-term use of an appropriate drain (e.g.,
corrugated drain, Malecot catheter). In addition, if there
is concern of undrained sepsis, potentially being fed
from a supralevator source, then an urgent inpatient
MRI scan will be required.
There is no requirement for wound packing following
abscess drainage [116], although its role is currently
under investigation in a multicenter randomized con-
trolled trial in the UK [117]. Packing may have a limited
role for short-term hemostatic requirements.
If an associated anal fistula is obvious at the time of
abscess drainage without any probing, then a loose
draining seton should be inserted. The loose draining
seton should be low profile and made of a soft material
of the surgeons choice, avoiding any bulky knots and
avoiding any firm suture material such as nylon. There
should be no attempt to lay the fistula open at the same
time, in order to minimise tissue disruption and preserve
future anal function.
This approach will allow subsequent treatment plan-
ning with the patient, then being an active participant in
the multidisciplinary management decisions required to
minimize future symptoms and maximize the chance of
potential fistula healing [118]. When sepsis is present,
there is no role for attempts at surgical adjuncts to fis-
tula healing, such as fibrin glue, fistula plug, LIFT, ad-
vancement flap, VAAFT, FiLac, and stem cells, in the
emergency setting.
In order to plan future treatment with the patient and
IBD multidisciplinary team, it is essential to know if
there is associated active proctitis in association with the
perianal sepsis. For this reason, an assessment of the rec-
tal mucosa should be made at the time of abscess drain-
age, either in the form of rigid or flexible sigmoidoscopy.
Conclusions
Complicated inflammatory bowel disease requires a
multidisciplinary approach because of the complexity of
this group of different diseases in the urgent/emergency
setting with the aim of obtaining good functional out-
comes and to decrease stoma rates where possible.
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These guidelines represent an effort to summarize
high-quality evidence and expert opinion to help acute
care surgeons and emergency surgeons in managing an
acute abdomen or perineum in patients presenting
acutely with complications of UC and CD.
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